Prime Medicine Inc

PRME is in an Early Stage 1 consolidation range after a prolonged downtrend, with the 9 and 21 EMAs having repaired and turned slightly upward. The Bullish Pivot Point pattern signals failed downside control and structural repair, giving a bullish medium-term mean-reversion bias against a bearish secular trend. Execution favors a Buy Now stance on a pullback into the rising EMA support zone within the base.

• ↑Q2 revenue beat by 4.4% and EPS beat by 6.3%
• ↑Net loss narrowed 20% YoY to $42.1M
• ↓Earnings yield is negative and profitability remains weak